

## 6. REFERENCES

- [1] Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orłowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. *N Engl J Med*. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. PMID: 35045221.
- [2] Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orłowski R, Miura T, Makker V, Fujiwara K. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. *Cancer Sci*. 2022 Oct;113(10):3489-3497. doi: 10.1111/cas.15436. Epub 2022 Jul 26. PMID: 35612971; PMCID: PMC9530883.
- [3] Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. *Cancer*. 2010 Jan 15;116(2):355-61. doi: 10.1002/cncr.24769. PMID: 19924790; PMCID: PMC2811766.
- [4] Japan Society of Gynecologic Oncology guide line of endometrial cancer.
- [5] Ghasemi D, Ameli F, Nili F, Edjtemaei R, Sheikhhasani S. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study. *BMC Cancer*. 2022 Dec 29;22(1):1362. doi: 10.1186/s12885-022-10478-7. PMID: 36581850; PMCID: PMC9801577.
- [6] Rousset-Rouviere S, Rochigneux P, Chrétien AS, Fattori S, Gorvel L, Provansal M, Lambaudie E, Olive D, Sabatier R. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. *Biomedicines*. 2021 Jun 2;9(6):632. doi: 10.3390/biomedicines9060632. PMID: 34199461; PMCID: PMC8228955.
- [7] Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. *J Clin Oncol*. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. PMID: 32716739; PMCID: PMC7479760.
- [8] Kitano S, Fujiwara Y, Shimizu T, Iwasa S, Yonemori K, Kondo S, Shimomura A, Koyama T, Ebata T, Ikezawa H, Hayata N, Minoshima Y, Miura T, Kubota T, Yamamoto N. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2022 Dec;90(6):523-529. doi: 10.1007/s00280-022-04480-w. Epub 2022 Oct 26. PMID: 36289094.

[9] Makker V, Taylor MH, Oaknin A, Casado Herraiez A, Orlowski R, Dutta L, Ren M, Zale M, O'Malley DM. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. *Oncologist*. 2021 Sep;26(9):e1599-e1608. doi: 10.1002/onco.13883. Epub 2021 Jul 30. PMID: 34190370; PMCID: PMC8417842.

[10] NCCN guideline for Endometrial carcinoma

[11] Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. *Future Oncol*. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PMID: 33300372.

[12] Liu K, Zhu Y, Zhou Y, Zhang Y, Zhu H. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis. *Gynecol Oncol*. 2022 Sep;166(3):582-588. doi: 10.1016/j.ygyno.2022.06.015. Epub 2022 Jul 1. PMID: 35781166.

[13] Humber CE, Tierney JF, Symonds RP, Collingwood M, Kriwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Ann Oncol* 2007 ; 18 : 409-20

[14] Lorusso D, Danesi R, Locati LD, Masi G, De Giorgi U, Gadducci A, Pignata S, Roberto S, Savarese A, Valabrega G, Zamagni C, Colombo N. Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma. *Front Oncol*. 2022 Sep 21;12:979519. doi: 10.3389/fonc.2022.979519. PMID: 36212444; PMCID: PMC9535356.

[15] <https://c2h.niph.go.jp>

[16] Barrington DA, Haight PJ, Calhoun C, Tubbs C, Cohn DE, Bixel KL. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost- effectiveness analysis. *Gynecol Oncol*. 2021 Sep;162(3):626-630. Doi: 10.1016/j.ygyno.2021.06.014. Epub 2021 Jun 18. PMID: 34148720.

[17] Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. *Gynecol Oncol*. 2021 Aug;162(2):249-255. Doi: 10.1016/j.ygyno.2021.05.038. Epub 2021 Jun 6. PMID: 34103196; PMCID: PMC8663341.

[18] Arora S, Balasubramaniam S, Zhang W, Zhang L, Sridhara R, Spillman D, Mathai JP, Scott B, Golding SJ, Coory M, Pazdur R, Beaver JA. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. *Clin Cancer Res*. 2020 Oct 1;26(19):5062-5067. Doi: 10.1158/1078-0432.CCR-19-3979. Epub 2020 Apr 15. PMID: 32295834.

- [19] Chen, D., Mellman, I. Elements of cancer immunity and the cancer-immune set point. *Nature* **541**, 321–330 (2017). <https://doi.org/10.1038/nature21349>
- [20] Thurgar E, Gouldson M, Matthijsse S, Amonkar M, Marinello P, Upadhyay N, Nwankwo C, Aguiar-Ibáñez R. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. *J Med Econ.* 2021 Jan-Dec;24(1):675-688. Doi: 10.1080/13696998.2021.1917140. PMID: 33866938.
- [21] Zheng Z, Yang L, Xu S, Zhu H, Cai H. Cost-effectiveness analysis of 25envatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China. *Front Pharmacol.* 2022 Sep 30;13:944931. Doi: 10.3389/fphar.2022.944931. PMID: 36249813; PMCID: PMC9561308.
- [22] Feng M, Chen Y, Yang Y, Li Q. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis. *Front Public Health.* 2022 May 10;10:881034. doi: 10.3389/fpubh.2022.881034. PMID: 35619813; PMCID: PMC9127138.
- [23] Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. *Int Immunopharmacol.* 2021 Feb;91:107281. doi: 10.1016/j.intimp.2020.107281. Epub 2020 Dec 16. PMID: 33338862.
- [24] Maiorano BA, Maiorano MFP, Cormio G, Maglione A, Lorusso D, Maiello E. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. *Front Oncol.* 2022 Apr 14;12:844801. doi: 10.3389/fonc.2022.844801. PMID: 35494078; PMCID: PMC9047829.